Donanemab-azbt (Kisunla) is administered by intravenous infusion every four weeks and can rarely cause a life-threatening allergic reaction and swelling.
Notes on verification
Confirmed by FDA approval announcement, official prescribing label, and Drugs.com reproduction of label; consistent details across independent primary and secondary sources. [tier=silver indep_score=0.925 clusters=2 claim_tier=notable]
Sources
- Dementia - Diagnosis and treatment (seed:health_and_medicine)
- https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease (corroboration)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf (corroboration)
- https://www.drugs.com/pro/kisunla.html (corroboration)